Journal of the American Society of Hypertension
Volume 3, Issue 2 , Pages 113-118 , March 2009

Hypertension: a policy perspective, 1976–2008

  • William B. Stason, MD, MSci

      Affiliations

    • Corresponding Author InformationCorresponding author: William B. Stason, MD, MSci, School of Public Health, Harvard University and Heller School for Social Policy and Management, Brandeis University, Lincoln, Massachusetts 01773. Tel: 781-258-3419; fax: 781-736-3905.

Received 27 August 2008 ,Accepted 10 December 2008.

References 

  1. American Heart Association Statistical Update – 2008. Circulation. 2008;117:e25–e2146
  2. Weinstein MC, Stason WB. Hypertension: a policy perspective. Harvard: University Press; 1976;
  3. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. New Engl J Med. 1977;296:716–721
  4. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. New Engl J Med. 1977;296:732–739
  5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LE, Izzo JL, et al. The JNC 7 Report. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560–2572
  6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997
  7. Heidenreich PA, Davis BR, Cutler JA, Furberg CD, Lairson DR, Shlipak MG, et al. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Gen Intern Med. 2008;23:509–516
  8. Hansson L, Zanchetti A, Carruthers SC, Dahölf B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension; principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755–1762
  9. Jonsson B, Hannson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension. J Intern Med. 2003;253:472–480
  10. Shepard DS, Hodgkin D. Cost effectiveness of intensive treatment of hypertension. Am J Managed Care. 1998;4:S765–S770
  11. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified, hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542–2551
  12. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension. Can better care cost less?. JAMA. 2004;291:1850–1856
  13. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman M, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534–2544
  14. Gemmill M, Thomson S, Mossialos E. What impact do prescription drug charges have on efficiency and equity? Evidence from high income countries. Int J Equity Health. 2008;7:12
  15. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of copayments on medication adherence during the first 2 years of prescription drug treatment. J Occup Environ Med. 2005;49:597–609
  16. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Managed Care. 2006;11:678–683
  17. Chernow ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Affairs. 2008;27:103–112
  18. Hsu J, Price M, Huang J, Brand R, Fung V, Hui R, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354:2349–2359
  19. Thorpe KE. Cost sharing, caps on benefits, and the chronically ill—a policy mismatch. N Engl J Med. 2006;354:2385–2386
  20. Rosenthal MB, Landon BE, Howitt K, Song HSR, Epstein AM. Climbing up the pay-for-performance learning curve: where are the early adopters now?. Health Affairs. 2007;26:1674–1682
  21. Rosenthal MB, Landon BE. Normand S-LT, Frank RG, Ahmad TS, Epstein AM. Employers' use of value-based purchasing strategies. JAMA. 2007;298:2281–2288
  22. Snyder L, Neubauer RL. Pay-for-performance principles that promote patient-centered care: an ethics manifesto. Ann Intern Med. 2007;147:792–794
  23. Institute for Health Improvement. Quality rules. 2008 Progress Report. www.IHI.org.

 Conflict of interest: none.

PII: S1933-1711(08)00219-2

doi: 10.1016/j.jash.2008.12.001

Journal of the American Society of Hypertension
Volume 3, Issue 2 , Pages 113-118 , March 2009

Article Tools